Stimulating results with stimulatory antibodies

Blood

Volumn 110, Issue 1, 2007, Pages 6-7

  Mapara, Markus Y ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE ANTIBODY; CD20 ANTIBODY; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; RITUXIMAB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; GENE EXPRESSION; HUMAN; LICHENOID; LUNG FIBROSIS; MORBIDITY; MORTALITY; MYOFIBROBLAST; NOTE; POLYMYOSITIS; PRIORITY JOURNAL; SJOEGREN SYNDROME; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

EID: 34347407157     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-04-082891     Document Type: Note

References (4)

1. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354:2667-2676.
2. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105:2973-2978.
3. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756-762.
4. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56:311-322.